Counts of positive / neutral / negative news items — not a price chart.
Informational only — not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
AstraZeneca's Enhertu Cancer Drug Gains Approval, Boosting Prospects
Direct news · High influence · Long term
AstraZeneca Secures Two EU Cancer Approvals, Advances Lung Cancer Trial
Direct news · High influence · Long term
AstraZeneca Unveils Strong Phase 3 Bone Disease Drug Data, Targeting $5 Billion Sales
Direct news · High influence · Long term
AstraZeneca Secures $1.7 Billion Kidney Drug Discovery Deal with Chinese Partner CSPC
Direct news · Medium influence · Long term
AstraZeneca Collaborates on NSCLC Trial: Pipeline Expansion in Focus
Direct news · Medium influence · Long term
Macro, commodity, FX and regulatory forces that moved AZN in this range, with the stories behind each.
No indirect-driver news for AZN in this range.
Also monitored for AZN (no news in this range): Sterling (GBP), UK Budget / fiscal & tax, US Fed / global rates & risk.
Sign up free to track AZN, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track AZN — freeInformational only — not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
AstraZeneca Collaborates on NSCLC Trial: Pipeline Expansion in Focus
